

Table 9.6b
Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009
Recipients with Liver Transplants

	Discharge Regimen (w/ or w/o Steroids Use)										All
	CyA	Tac	CyA+ MMF	Tac+ MMF	CyA+ Aza	Tac+ Aza	Siro+ MMF	CyA+ Siro	Tac+ Siro	Other	
Functioning Graft with Immunosuppression Info at Discharge	253	7,396	1,215	18,609	39	117	217	166	195	1,365	29,572
% of All Regimens	0.9%	25.0%	4.1%	62.9%	0.1%	0.4%	0.7%	0.6%	0.7%	4.6%	100.0%
Induction Drug											
Atgam/NRATG/NRATS	0.4%	1.4%	0.2%	0.5%	2.6%	0.0%	0.0%	0.0%	0.0%	1.2%	0.8%
OKT3	0.4%	0.8%	0.9%	3.1%	0.0%	0.9%	0.5%	0.6%	3.1%	3.6%	2.4%
Thymoglobulin	6.3%	6.2%	7.4%	10.1%	2.6%	28.2%	18.9%	4.2%	19.0%	19.9%	9.6%
Zenapax	11.9%	4.6%	12.7%	6.1%	2.6%	5.1%	6.5%	69.9%	6.7%	14.8%	6.8%
Simulect	5.9%	5.1%	13.7%	7.0%	5.1%	3.4%	13.8%	4.2%	6.7%	18.3%	7.3%
Campath	1.2%	3.5%	0.2%	0.4%	0.0%	1.7%	0.0%	0.0%	2.1%	2.7%	1.3%
No Induction Drugs Recorded	74.7%	79.3%	66.4%	76.1%	87.2%	60.7%	61.8%	24.1%	65.6%	76.7%	76.0%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.